Benefits
Immune System Support
Laboratory work shows echinacea alkylamides and polysaccharides act on macrophages, natural killer cells and T-cells. That has not carried over cleanly into people. The 719-person Annals of Internal Medicine trial measured nasal interleukin-8 and neutrophil counts during real colds and found no significant difference versus placebo, and illness lasted 6.34 days on echinacea versus 6.87 on placebo, which was not statistically significant. The human immune signal that does exist is narrower: two manufacturer-funded prevention trials reported fewer virally confirmed colds.
Fewer Colds: A Small and Contested Effect
The answer depends on which synthesis you read. The 2007 Lancet Infectious Diseases meta-analysis of 14 studies reported 58 percent lower odds of developing a cold (odds ratio 0.42, 95% CI 0.25 to 0.71) and 1.4 fewer days of illness, but it pooled very different products, its heterogeneity test was significant, and it predates the largest trials. The 2014 Cochrane review of 24 double-blind trials in 4,631 people found that none of the 12 prevention comparisons reached statistical significance on its own, and that a post hoc pooling suggested only a 10 to 20 percent relative risk reduction the reviewers called of questionable clinical relevance. An independent 2019 meta-analysis found a 22 percent lower risk of infection (risk ratio 0.78, 95% CI 0.68 to 0.88) but no effect on duration. For treating a cold you already have, Cochrane concluded echinacea has not been shown to provide benefit.
Anti-Inflammatory Activity in Cell Culture Only
This is laboratory evidence only. Alkylamides and caffeic acid derivatives change cytokine output in cell culture, and depending on the preparation and the cell type they have been reported to move the same cytokines in both directions. No human trial on this page measured an inflammatory outcome that improved. The one that tried, the 719-person Annals trial, found no significant change in nasal interleukin-8 or neutrophil counts during actual colds.
Antioxidant Compounds, No Human Outcome Measured
Echinacea contains cichoric acid and other caffeic acid derivatives that scavenge free radicals in test-tube assays. The only human antioxidant data is an 11-person pilot with no control group and no randomization, which reported less free-radical-induced red cell breakdown after 14 days. An uncontrolled before-and-after study cannot show that a supplement caused a change, so this describes the plant's chemistry rather than a demonstrated effect of taking it.
Wound Healing: Skin Creams Only, Not Oral Echinacea
The wound-healing claims for echinacea come from creams and ointments applied to the skin. That is a different route of administration from a capsule or tincture and nothing about it carries over to swallowing echinacea. No oral trial has shown a wound-healing or skin benefit.
Mechanism of action
Immunomodulation
Echinacea enhances the activity of the immune system by stimulating phagocytosis (the process by which immune cells like macrophages and neutrophils engulf pathogens). It increases the production of cytokines, such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha (TNF-α), which regulate immune responses. Polysaccharides such as arabinogalactans activate immune cells including T-cells and natural killer cells in laboratory systems. Two honest caveats belong here. Echinacea preparations have been reported both to raise and to lower the same cytokines depending on the extract, the cell type and the dose, so this is not one consistent story. And the only human trial on this page that measured a cytokine during a real cold (nasal interleukin-8, in 719 people) found no significant change.
Anti-inflammatory Effects
Echinacea contains alkamides and caffeic acid derivatives (e.g., cichoric acid, echinacoside) that inhibit inflammatory pathways, such as cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, reducing the production of pro-inflammatory mediators like prostaglandins and leukotrienes. This anti-inflammatory action may help alleviate symptoms of infections, such as sore throat or tissue inflammation during colds.
Antimicrobial Activity
In cell culture, echinacea extracts show mild antibacterial, antiviral and antifungal activity, attributed to alkylamides and phenolic compounds. This has not been shown to produce a direct antimicrobial effect in people at supplement doses. It may disrupt microbial cell membranes or inhibit viral replication, particularly against respiratory viruses like influenza or rhinovirus, though direct antiviral effects are less pronounced than immunomodulatory effects.
Antioxidant Effects
Phenolic compounds, such as cichoric acid and echinacoside, act as antioxidants, neutralizing free radicals and reducing oxidative stress, which supports overall immune function and tissue repair.
Interaction with the Endocannabinoid System
Alkamides in echinacea can bind to cannabinoid receptors (CB2), which are primarily found in immune cells. This interaction may modulate immune responses and contribute to anti-inflammatory effects.
Clinical trials
Jawad 2012, Evidence-Based Complementary and Alternative Medicine. Randomized, double-blind, placebo-controlled trial in 755 adults in good health who reported at least 2 colds a year, over 4 months. Dose was 2,400 mg/day of an alcoholic extract of freshly harvested Echinacea purpurea (95 percent aerial parts, 5 percent root), raised to 4,000 mg/day during a cold. Two of the authors, Schoop and Suter, are scientists at A. Vogel, the company that makes Echinaforce, and the paper's conflict of interest statement names only the other three authors as having none.
755 adults in good health who had at least 2 colds a year, over 4 months.
Fewer total cold episodes, fewer cumulated cold days and fewer painkiller-treated episodes than placebo, and adverse events were no more frequent than placebo (293 with echinacea, 306 with placebo). Read one limit into it: the authors state the preventive effects increased with therapy compliance and adherence to protocol, which is a weaker analysis than the primary comparison. Two of the authors are scientists at the company that sells the product, and this specific extract has not been independently replicated.
Ogal 2021, European Journal of Medical Research. Randomized, double-blind trial in 203 children aged 4 to 12, of whom 201 received study medication. Echinaforce Junior 400 mg three times daily (1,200 mg/day) versus tablets containing 50 mg vitamin C as the comparator, given over two 2-month blocks separated by a 1-week break. There was no placebo arm. Funded by A. Vogel AG; one author is a company employee.
203 children aged 4 to 12 randomized, 201 treated, over about 4 months.
429 cold days occurred with echinacea versus 602 with vitamin C, and echinacea prevented 32.5 percent of respiratory infection episodes (odds ratio 0.52, 95% CI 0.30 to 0.91). Six children (5.8 percent) on echinacea needed antibiotics versus 15 (15.3 percent) on vitamin C. Weigh that against the design: the comparator was vitamin C rather than placebo, the trial was funded by the manufacturer with a company employee as an author, and it has not been independently replicated. Antibiotic decisions for a child are made by the child's doctor.
Barrett 2010, Annals of Internal Medicine. Randomized trial in 719 people aged 12 to 80 with new-onset colds, in four arms: no pills, blinded placebo, blinded echinacea, and open-label echinacea. Dose was the equivalent of 10.2 g of dried Echinacea angustifolia and E. purpurea root in the first 24 hours and 5.1 g on each of the next 4 days. Funded by the NIH National Center for Complementary and Alternative Medicine, with no industry sponsor.
719 people aged 12 to 80 with a new cold.
Null. Mean illness lasted 6.34 days on blinded echinacea versus 6.87 days on blinded placebo, a 0.53-day difference that was not statistically significant (95% CI, 1.25 days shorter to 0.19 days longer; P = 0.075). Mean global severity was 236 versus 264, a 28-point trend that was also not significant (P = 0.089). Nasal interleukin-8 and neutrophil counts did not differ significantly either. The authors' conclusion: these results do not support the ability of this dose of the echinacea formulation to substantively change the course of the common cold.
Grimm and Müller 1999, American Journal of Medicine. 109 adults with more than 3 colds or respiratory infections in the previous year were randomized to 4 mL of Echinacea purpurea fluid extract or 4 mL of placebo juice twice daily for 8 weeks; 108 were analysed after one withdrawal before the first dose.
108 adults with frequent cold history. 8-week intervention.
Null on every endpoint. 35 of 54 (65 percent) in the echinacea group and 40 of 54 (74 percent) on placebo had at least one cold or respiratory infection (relative risk 0.88, 95% CI 0.60 to 1.22). Median duration was 4.5 days versus 6.5 days, not significant (P = 0.45). There was no significant difference in the number of infections in any severity category. Side effects were reported by 20 percent on echinacea and 13 percent on placebo. The authors concluded the extract did not significantly decrease the incidence, duration or severity of colds.
Tiralongo 2012, Evidence-Based Complementary and Alternative Medicine. Randomized, double-blind, placebo-controlled trial in 175 adults flying economy class from Australia to America, Europe or Africa for 1 to 5 weeks, taking a root extract standardized to 4.4 mg alkylamides or placebo. The outcome was a self-reported upper respiratory symptom survey; no infection was laboratory-confirmed.
175 adults on long-haul economy flights.
Respiratory symptoms rose significantly in both groups during travel. The echinacea group had lower symptom scores than placebo at the very edge of significance (P = 0.05). No infection was confirmed by testing, so this says nothing about infection rates, and the authors worded their own conclusion as may have preventive effects. Small trial, soft self-reported endpoint.
This card is a systematic review, not a study in people. Karsch-Völk and colleagues, Cochrane Database of Systematic Reviews 2014, covering 24 double-blind trials that contributed 33 comparisons in 4,631 participants against placebo, across many different species, plant parts and extraction methods. Ten trials were rated low risk of bias, six unclear and eight high.
Not a study population: 4,631 participants pooled across 24 separate trials.
The reviewers refrained from pooling the main analysis because the trials were too clinically different. None of the 12 prevention comparisons reporting the number of people with at least one cold episode found a statistically significant difference, though a post hoc pooling suggested a 10 to 20 percent relative risk reduction. Of the 7 treatment trials reporting cold duration, only 1 showed a significant effect. Dropouts and adverse effects did not differ significantly, though prevention trials showed a trend toward more dropouts for adverse events on echinacea. Their conclusion in their own words: echinacea products have not here been shown to provide benefits for treating colds, although it is possible there is a weak benefit from some echinacea products, with prophylaxis trials showing positive but non-significant trends whose potential effects are of questionable clinical relevance. Note that four of the six review authors had been involved in trials included in the review, and state they did not extract data or assess quality on their own studies.
Riemma 2022, Medicina (Kaunas). Single-blind three-arm randomized trial at one Italian colposcopy unit: an oral Echinacea angustifolia plus E. purpurea supplement with vaginal hyaluronic acid capsules, versus the oral echinacea supplement alone, versus the vaginal capsules alone, for 3 months in 153 reproductive-aged women with CIN-1.
153 women with CIN-1 on cervical cytology, at one Italian centre, under gynaecological supervision.
Read the three arms carefully. At 12 months, persistent CIN-1 was 5 of 51 with oral echinacea plus vaginal hyaluronic acid, 15 of 48 with the oral echinacea alone, and 14 of 48 with the vaginal gel alone. Echinacea by itself did not separate from the gel by itself, so nothing here is attributable to echinacea on its own. The trial was single-blind, in 153 women at a single Italian centre, and the authors state the limited sample size reduces the quality of the evidence. Abnormal cervical cytology is diagnosed and managed by a doctor; no supplement treats it.